The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation

Clinical Infectious Diseases

Volumn 49, Issue 11, 2009, Pages

  Travi, Giovanna ^a,b   Pergam, Steven A ^a   Xie, Hu ^a   Carpenter, Paul ^a   Kiem, Hans Peter ^a   Corey, Lawrence ^a   Boeckh, Michael J ^a  

^a USA   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN TYROSINE KINASE INHIBITOR; TACROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; VIRUS ACTIVATION; YOUNG ADULT;

EID: 72849109573     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648120     Document Type: Article

References (12)

1. Mumprecht S, Matter M, Pavelic V, Ochsenbein AF. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 2006; 108(10): 3406-3413
2. Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factoralpha receptor activation is required for human cytomegalovirus infection. Nature 2008; 455(7211):391-395
3. Schang LM. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Review of Antiinfective Therapy 2006; 4(6):953-956
4. Durosinmi MA, Ogbe PO, Salawu L, Oyekunle AA. Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour. Singapore Medical Journal 2007; 48(1):e16-8.
5. Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicellazoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9(3):976-980 (Pubitemid 36323700)
6. Erard V, Guthrie KA, Varley C, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110(8):3071-3077
7. Nakamae H, Kirby KA, Sandmaier BM, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15(6):694-703.
8. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34(8): 1094-1097
9. Steegmann JL, Moreno G, Alaez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003; 88(7):762-768
10. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptormediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105(6):2473-2479
11. + peripheral blood progenitor cells. Blood 2004; 103(2):538-544
12. + T-cell tolerance. Blood 2005; 105(3):1135-1143